CompaniesInvestorsPeople
Home
Loading

aVenture is in Beta: research coverage is expanding as we build, so please independently verify key details before making investment decisions.

aVenture is in Beta: research coverage is expanding as we build, so please independently verify key details before making investment decisions.

Get in Touch

  • Contact

  • Request a Demo

  • Request Data Updates

  • Add a Company

Research

  • Companies

  • Investors

  • People

aVenture

  • Download App

  • Pricing

Download the aVenture Research beta for iOS and iPadOSDownload aVenture Research on the Mac App Store

Resources

  • Documentation

  • Use Cases

  • CLI

  • MCP

  • Feature Requests

  • Sitemap

Member

Backed by

Ask AI about aVenture

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy · Terms of Service

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading
Home›
Companies›
DDReg Pharma›
Library
DDReg Pharma

DDReg Pharma

DDReg Pharma provides regulatory consulting and pharmacovigilance services to pharmaceutical and biopharma companies through in-house reg-tech platforms.

Gurugram, Haryana, IN🇮🇳
Founded
2009
Loading
Overview
Compare
Employees
News
Library

DDReg Pharma - Library

ddregpharma.com·Crawled Oct 10, 2026·

Topics

Publication type

Content origin
Row density

Blog

6 pages
  1. Regulatory Knowledge: DDReg Pharma/regulatory-knowledge

    Regulatory knowledge refers to understanding all the terms that are required to pharmaceutical, medical device, and drug products.

  2. What is a Drug Master File and Its Types?/what-is-a-drug-master-files

    A Drug Master File (DMF) is a submission to regulators containing key information on the chemistry, manufacturing, and control (CMC) of a pharmaceutical product.

  3. What is a New Drug Application(NDA)?/what-is-a-new-drug-application

    A New Drug Application (NDA) is a formal submission made by a pharmaceutical company to regulatory authorities.

  4. What is a Unique Device Identification?/what-is-a-unique-device-identification

    The Unique Device Identification (UDI) is a unique alphanumeric or numeric code that helps to identify and track medical devices throughout their lifecycle, from manufacturing to patient use.

About

2 pages
  1. Global Regulatory & Pharmacovigilance Solutions - DDReg Pharma/global-reach

    Partner with DDReg for global RA & PV services, ensuring compliance, faster approvals, and expert support across FDA, EMA, MHRA, TGA, SFDA & more.

  2. Life Sciences Industry Regulatory Solutions Company/company

    DDReg Pharma is a leading life science regulatory solutions consultant that provides global pre- and post-approval solutions for the Life science industry.

Contact

1 page
  1. Contact DDReg Pharma | Regulatory Affairs & Pharma Consulting./contact-us

    Get in touch with DDReg Pharma for regulatory affairs, medical writing, and pharmacovigilance support for global pharma companies.

Homepage

1 page
  1. Homepage/

    DDReg is a life sciences consulting firm supporting pharma, biotech, food, cosmetics & medical device companies in bringing products to market efficiently.

Coverage

7 items
  1. Excellence in Pharma Service Company of the Year | FE Pharmaresource.ddregpharma.com/uncategorized/ddreg-pharma-named-excellence-in-pharma-service-company-of-the-year-at-fe-pharma-summit-awards-2026/

    DDReg Pharma is honored as Excellence in Pharma Service Company of the Year at the FE Pharma Summit & Awards 2026. The company says it continues to set benchmarks in regulatory affairs and pharma services globally.

    Apr 2026 · DDReg PharmaNews article

  2. DDReg Honored at ET Health Conclave 2025 for Excellence in Life Sciences Servicesresource.ddregpharma.com/news-and-events/ddreg-honored-at-et-health-conclave-2025-for-excellence-in-life-sciences-services/

    DDReg Pharma is honored at ET Health Conclave 2025 for excellence in life sciences services. The announcement does not specify an award category or provide further details about the recognition.

    Aug 2025 · DDReg PharmaNews article

  3. DDReg Celebrates 16 Years of Enabling Access to Global Healthcareissuewire.com/ddreg-celebrates-16-years-of-enabling-access-to-global-healthcare-1836711546441143

    DDReg Celebrates 16 Years of Enabling Access to Global Healthcare - IssueWire

    Jul 2025 · IssuewireNews article

  4. Quantiphi, DDReg Partner to Transform Regulatory Reporting in Life Sciences Through AItheprint.in/ani-press-releases/quantiphi-ddreg-partner-to-transform-regulatory-reporting-in-life-sciences-through-ai/2344437/

    Quantiphi, a global AI-first digital engineering company, and DDReg, a global leader in regulatory expertise, announce a partnership to use AI to address regulatory challenges. The collaboration targets pharmaceutical, biotechnology, medical device, and cosmetics companies seeking to bring innovations to market more quickly.

    Nov 2024 · ThePrintNews article